Quintessence Biosciences, Inc. is a biopharmaceutical company focused on development of novel protein-based therapeutics as anti-cancer agents. The Company’s products are based on the EVade™ Ribonuclease Technology which allows for the engineering of human proteins (ribonucleases) for the treatment of human diseases.
The EVade™ Ribonuclease technology is covered by patents acquired
by the Company through an exclusive license with the University
of Wisconsin. The Company has advanced lead candidate QBI-139
into a Phase I human clinical trial at the University of Wisconsin
Comprehensive Cancer Center.Second generation products are under
development and pre-clinical work is ongoing.